HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors
Clinical Scorecard: HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors
At a Glance
Category Detail
Condition Type 1 Diabetes
Key Mechanisms Deceased donor pancreatic islet cells may restore insulin production in recipients.
Target Population Individuals with type 1 diabetes requiring insulin therapy.
Care Setting Regulatory framework for transplantation of deceased donor islet cells.
Key Highlights
HHS is evaluating FDA regulations that may limit access to islet cell therapies. Islet transplantation may decrease or eliminate the need for insulin in recipients. Feedback is sought on whether unmodified islet cells should be classified as organs. Current FDA oversight ensures safety and effectiveness of islet cell products. Public comments are invited until November 8, 2026.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with type 1 diabetes potentially benefiting from islet cell transplantation.
Islet cells from deceased donors may provide a life-changing therapy for insulin production.
Clinical Best Practices
Maintain stringent safety and quality requirements in islet cell transplantation. Consider patient access barriers arising from current FDA regulations.
Related Resources & Content